GRACE conference in Boston

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online.

PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors and about various combination trials that have or will soon start. Also has a chart on various mutations and how some ALK inhibitors do against them.

http://www.oncology.tv/Portals/16/CancerGraceSlides/Shaw.pptx
Look below for a posted comment on other presentations from the conference.

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

One Response to GRACE conference in Boston

Leave a Reply